Hemolysis, Elevated Liver Enzymes, Low Platelets Syndrome Superimposed on Hemolytic Uremic Syndrome

Síndrome HELLP sobreposta a síndrome hemolítica-urêmica

Inês Martins, Madalena Gomes Conceição, Paulo Pereira Gomes, Nuno Clode

1 Department of Obstetrics, Gynecology and Reproductive Medicine, Centro Hospitalar Lisboa Norte, Hospital Santa Maria (CHLN-HSM), Lisbon, Portugal
2 Department of Obstetrics and Gynecology, Hospital CUF Descobertas, Lisbon, Portugal
3 Intensive Care Unit, Hospital CUF Descobertas, Lisbon, Portugal
4 Department of Medicine, Universidade de Lisboa, Lisbon, Portugal

Address for correspondence
Inês Martins, MD, MSci, Departamento de Obstetrícia, Ginecologia e Medicina da Reprodução do CHLN-HSM, Avenida Prof. Egas Moniz, 1649-035 Lisboa, Portugal (e-mail: martins.p.ines@gmail.com).

Abstract
A pregnancy complicated by typical hemolytic uremic syndrome (HUS) and hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome is reported. At 20 weeks of gestation, a case of HUS was diagnosed, with Shiga toxin-producing Escherichia coli identified. Plasmapheresis allowed continuation of the pregnancy for 5 weeks. Superimposed preeclampsia and HELLP syndrome were diagnosed after the establishment of nephrotic range proteinuria, hypertension and recurrence of hemolysis. This is a singular case, as it demonstrates that HELLP syndrome can superimpose upon HUS, a fact that can impact future research on reproductive immunology. It also reminds clinicians that the overlapping of clinical and laboratory findings in HELLP syndrome makes the diagnosis of other thrombotic microangiopathies during pregnancy a clinical challenge.

Keywords
► HELLP syndrome
► hemolytic uremic syndrome
► thrombotic microangiopathies

Resumo
Descrie-se um caso clínico em que às 20 semanas de gestação é diagnosticada síndrome hemolítica-urêmica com isolamento de Escherichia coli produtora de toxina Shiga. A terapêutica com plasmaferese permitiu a manutenção da gravidez ao longo de 5 semanas. O surgimento de proteinúria nefrótica, hipertensão e recorrência de hemólise conduziu ao diagnóstico de sobreposição de pré-eclâmpsia e síndrome HELLP. Este caso é singular, pois demonstra que a síndrome HELLP pode se sobrepor a uma síndrome hemolítica-urêmica, um fato que pode influenciar futuras investigações no âmbito de imunologia reprodutiva. Reforça-se, ainda, que o diagnóstico de outras microangiopatias trombóticas durante a gestação é um desafio clínico ocasionado pela sobreposição de manifestações clínicas e laboratoriais com a síndrome HELLP.
**Introduction**

Thrombotic microangiopathies are characterized by endothelial cell dysfunction, microvascular thrombosis, platelet consumption and reduced tissue perfusion.\(^1,2\) As blood flows through partially constricted microvessels, hemolysis occurs.\(^2\) In pregnancy, its most common form is the hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome.\(^1-3\) Its pathogenesis is not established, and hypotheses include alteration in the maternal-fetal immune balance, or placenta instigated liver-targeted acute inflammatory condition, or a severe form of preeclampsia.\(^2\) The microvascular injury in HELLP syndrome is systemic, but mainly affects the liver.\(^1-3\)

Hemolytic uremic syndrome (HUS) is another life-threatening thrombotic microangiopathy characterized by hemolytic anemia, thrombocytopenia and acute kidney injury.\(^4\) Hypertension can occur due to the activation of the renin-angiotensin system associated with renal ischemia.\(^4\) Shiga toxin-producing Escherichia coli (STEC) is responsible for the typical form of the disease.\(^5\) It infects humans after the ingestion of contaminated food or water. Abdominal pain and hemorrhagic diarrhea develop within 3–7 days, and up to 10% of the infected patients (usually serotype O157) develop HUS 4–10 days after the onset of diarrhea. The microvascular injury is mediated by the Shiga toxin, and mainly affects the kidney.\(^1,2\) Non-STEC-HUS, or atypical HUS (aHUS), can have multiple etiologies associated with the dysregulation of the complement activation.\(^2\) At the onset, it is difficult to distinguish HUS/aHUS from thrombotic thrombocytopenic purpura (TTP), a thrombotic microangiopathy associated with markedly reduced activity of von Willebrand factor-cleaving metalloproteinase (ADAMTS13).\(^2,4\)

The authors report a case where both typical HUS and HELLP syndromes were diagnosed, elucidating the clinical challenge associated with this differential diagnosis.

**Case Presentation**

A 42-year-old pregnant patient (after in vitro fertilization), gravida 3 para 0, without significant medical or surgical history, was admitted at 20 weeks of gestation for severe abdominal pain and bloody diarrhea that started after ingesting vegetables grown in a family farm. Beside slight uterine contractions, no other symptoms/signs were present. On blood tests, only a slight leukocytosis (14,800/mm\(^3\)) and a high C-reactive protein (3.3 mg/dl) were noted. Since the abdominal ultrasound suggested appendicitis, a laparoscopic appendectomy was performed. The histological examination did not confirm the diagnosis. The patient, asymptomatic, was discharged the next day.

Four days later, she was reevaluated for sudden onset of peripheral and periorbital edema and oliguria, with normal blood pressure (BP). Laboratory tests (►Table 1, line1) were consistent with microangiopathic hemolytic anemia, thrombocytopenia and acute kidney injury. There was also microscopic hematuria and proteinuria, and a mild elevation of the aspartate aminotransferase (AST) and the alanine aminotransferase (ALT). Surgical complications were excluded. An obstetric ultrasound scan excluded signs of fetal distress, malformations or abnormalities. She was admitted for suspected typical HUS to the intensive care unit (ICU), where plasmapheresis was immediately started after red blood cell transfusion. Stool and blood samples were negative, but STEC serotype O157:H7 was identified in the urine culture. Plasma exchange therapy was performed daily for 4 days. Thereafter, it was performed according to the platelet count and the lactate dehydrogenase (LDH) level. The replacement fluid was 100% fresh frozen plasma (FFP) in the first two sessions and later, 50% albumin solution/50% FFP. Continuous hemodiafiltration was performed to avoid fluid overload (the volume balance was zero during the treatment). Anticoagulation was performed with heparin in the priming of the filter and by continuous infusion during the replacement. After an

<table>
<thead>
<tr>
<th>Time Point</th>
<th>Hemogl. (g/dl)</th>
<th>Platelets (l/mm(^3))</th>
<th>Creatin. (mg/dl)</th>
<th>AST/ALT (UI/l)</th>
<th>LDH (UI/l)</th>
<th>Haptoglobin levels</th>
<th>Blood smear</th>
<th>Proteinuria</th>
</tr>
</thead>
<tbody>
<tr>
<td>At onset (20 wks)</td>
<td>7.8</td>
<td>58,000</td>
<td>1.9</td>
<td>85/59</td>
<td>680</td>
<td>undetectable</td>
<td>schistocytes</td>
<td>Minor degree (+)</td>
</tr>
<tr>
<td>One week after initial plasma exchange therapy (21 wks)</td>
<td>9.8</td>
<td>155,000</td>
<td>2.0</td>
<td>36/39</td>
<td>257</td>
<td>normal range</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>After hypertension onset (23 wks)</td>
<td>8.5</td>
<td>50,000</td>
<td>2.0</td>
<td>37/29</td>
<td>246</td>
<td>undetectable</td>
<td>-</td>
<td>7,600 mg/24h</td>
</tr>
<tr>
<td>At the threshold of fetal viability (24 wks)</td>
<td>10.2</td>
<td>73,000</td>
<td>1.5</td>
<td>57/32</td>
<td>620</td>
<td>undetectable</td>
<td>schistocytes</td>
<td>14 186 mg/24h</td>
</tr>
<tr>
<td>At pulmonary edema onset (25 wks)</td>
<td>8.9</td>
<td>69,000</td>
<td>1.5</td>
<td>41/71</td>
<td>685</td>
<td>undetectable</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Two weeks after delivery</td>
<td>8.5</td>
<td>266,000</td>
<td>0.6</td>
<td>16/19</td>
<td>196</td>
<td>normal range</td>
<td>normal</td>
<td>187 mg/24h</td>
</tr>
</tbody>
</table>

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; Creatin., creatinine; Hemogl., hemoglobin; LDH, lactate dehydrogenase; wks, weeks.
initial worsening of the acute kidney injury (creatinine 2.5 mg/dl, max), the tests started to improve (► Table 1, line 2).

The patient developed hypertension (>160/110 mm Hg) 12 days after admission, requiring diuretic and antihypertensive therapies. The laboratory tests (► Table 1, line 3) were consistent with the recurrence of hemolysis and thrombocytopenia, mild elevation of transaminases and nephrotic range proteinuria. Complement activity and complement proteins were within the normal range, and the auto-antibodies were negative. Later, ADAMTS13 assessment was normal. Hemolytic uremic syndrome with superimposed preeclampsia and HELLP syndrome were considered on the differential diagnosis.

The patient refused to terminate the pregnancy. After the red blood cell transfusion and hypertension control, the tests were stable, and she was transferred to a tertiary-care hospital at 24 weeks of gestation (► Table 1, line 4). A course of betamethasone was administered for fetal lung maturity. An ultrasound scan revealed fetal growth restriction with normal umbilical artery Doppler velocimetry and amniotic fluid index.

At 25 weeks of gestation, she suffered a sudden relapse of microangiopathic hemolysis (► Table 1, line 5) and developed severe hypertension (200/120 mm Hg) and acute pulmonary edema refractory to therapy, suggesting severe preeclampsia and HELLP syndrome. After discussion with the parents, delivery of the fetus was decided upon. While on parenteral magnesium sulfate therapy, an emergency cesarean section was performed. The neonate (600 g, Apgar scores 4–7) was admitted at the neonatal ICU, but died the next day.

After the delivery, and without specific therapy, there was remission of the hemolysis, thrombocytopenia, proteinuria and the renal and hepatic injuries (► Table 1, line 6). The patient was discharged two weeks later on antihypertensive therapy, and no further recurrences have been diagnosed.

Discussion

Both HUS and HELLP syndromes are characterized by hemolysis and thrombocytopenia, with or without hypertension or proteinuria. Nonetheless, HELLP syndrome is far more frequent than HUS. Preeclampsia complicates 3–5% of pregnancies, and HELLP syndrome develops in 4–14% of women with severe preeclampsia. On the other hand, diagnosis of HUS/TTP during pregnancy or postpartum is very rare, probably 1 case in 100,000 pregnancies. Furthermore, STEC-HUS represents only 5–10% of the HUS cases in adults, compared with >90% of HUS in children.

Although both are thrombotic microangiopathies, the microvascular injury in the HELLP syndrome affects mostly the liver, while the kidney is the organ most affected in the HUS. Hence, transaminases are significantly elevated in the HELLP syndrome, but only mildly elevated in the HUS. In contrast, significant acute kidney injury is infrequently encountered in patients with HELLP syndrome, but it is an important feature in the clinical course of HUS.

Hemolytic uremic syndrome / thrombotic thrombocytopenic purpura should be suspected when hemolysis and thrombocytopenia are diagnosed during pregnancy in the presence of a normotensive pregnant woman, or when associated with hypertension and/or proteinuria before 24 weeks of gestation, or when the renal injury is worse than the liver injury. Whenever the patient presents with hemorrhagic diarrhea, STEC-HUS should be considered. In the case reported, the onset of the disease resembled the pathophysiology of STEC-HUS, with hemorrhagic diarrhea preceding hemolytic anemia, thrombocytopenia and acute kidney injury. In the absence of hypertension and severe liver injury, and presenting before 24 weeks of gestation, the diagnosis, although rare, appeared clear. During the diarrheic period, it is important to keep in mind that increased leucocyte count in the blood and increased serum C-reactive protein are risk factors for developing HUS after STEC infection, as occurred in this case.

Plasma exchange is the first line treatment for aHUS. Conversely, it has no beneficial effect to reduce nephropathy in STEC-HUS. Being difficult to distinguish typical HUS/aHUS/TTP at the onset, plasmapheresis without delay is suggested for most adult patients. While waiting for culture results, plasmapheresis was, therefore, instituted in our patient. The isolation of STEC serotype O157:H7 further corroborated the initial diagnosis, although it was isolated in the urine but not in the stool culture.

Later development of severe hypertension and nephrotic range proteinuria, associated with the recurrence of hemolytic anemia and thrombocytopenia, led to an even greater diagnosis challenge. Within the hypertensive disorders of pregnancy, HELLP syndrome has been categorized as a complicated form of severe preeclampsia. Although hypertension can also occur in the HUS, this usually happens during the acute phase of the disease, and does not occur with nephrotic proteinuria. Complete remission of the hemolysis, thrombocytopenia, proteinuria and the renal and hepatic injuries without a specific therapy after delivery corroborates the diagnosis of HELLP syndrome. To our knowledge, there are no other reports of HELLP superimposed on HUS.

There are no systematic reviews or randomized trials on HUS during pregnancy, probably due to its rarity. Stella et al reported a series of 14 cases of TTP/HUS in pregnancy or postpartum encountered in 4 tertiary-care centers over 8 years, which highlights the difficult differential diagnosis with HELLP. All the patients diagnosed with TTP/HUS before 24 weeks of gestation (n = 6) survived: 3 had term live births, 1 had a missed abortion, and 2 had intrauterine fetal death. On the case here reported, the pregnancy was continued for 5 weeks after the diagnosis of typical HUS, beyond the threshold of fetal viability. Despite this accomplishment, unfortunately, the neonate died.

The differential diagnosis also considered unusual HELLP syndrome postponed by plasma exchange therapy. A few studies investigated the role of plasma exchange in HELLP syndrome, and found that it can be an effective treatment for patients with persistent HELLP syndrome after delivery. After therapeutic plasma exchange, LDH and AST levels decrease, and platelets count increases. The mechanism of
action is still controversial. In theory, plasmapheresis removes from circulation aggregating, procoagulant and vasoactive factors released from activated platelets and endothelial cells, leading to renal and hepatic function improvement.

This case reinforces the difficulty in diagnosing HUS during pregnancy, considering that several clinical and laboratory findings overlap with the far more frequent HELLP syndrome. Hemolysis, elevated liver enzymes, low platelets syndrome superimposed upon STEC-HUS is a unique feature of this case that can impact future research.

References
1 Sibai BM. Imitators of severe pre-eclampsia. Semin Perinatol 2009;33(03):196–205